The global healthcare industry is undergoing a significant transformation, driven by increasing demand for remote patient monitoring, preventative care, and cost-effective solutions. Regulatory bodies are increasingly supporting digital health innovations that enhance patient safety and care accessibility. This technology aligns perfectly with these trends, offering a non-invasive, continuous monitoring solution that can reduce hospital visits, optimize rehabilitation protocols, and empower individuals with better self-management tools, fostering a competitive edge for early adopters in the digital health market.
Detects subtle laryngeal movements with high precision using resistive conductive materials, enabling more objective and detailed evaluation to improve rehabilitation quality.
Enables comfortable, continuous wear around the larynx with flexible materials and a simple structure, supporting daily swallowing status assessment outside clinical settings for early anomaly detection.
Reduces healthcare burden with non-invasive, simple application that requires no specialized medical skills, accelerating adoption in home healthcare and elder care facilities.
This patent protects a highly sensitive, resistive conductive material-based sensor for evaluating swallowing movements, specifically its configuration for comfortable body surface attachment and detection of laryngeal motion. The robust claims, secured after overcoming two office actions citing prior art, indicate a strong and stable intellectual property foundation.
This patent focuses on resistive sensor technology for laryngeal movement. White space exists in developing advanced AI for predictive dysphagia analytics, integrating with other physiological sensors for holistic health monitoring, or creating specific therapeutic feedback systems.
Considering annual medical costs for dysphagia (e.g., aspiration pneumonia treatment) and specialist rehabilitation/evaluation fees. Assuming aspiration pneumonia treatment costs ~$13.5K (AI est.) per case, and specialist evaluation/guidance costs ~$2.0K (AI est.) per person/year. This technology could reduce aspiration pneumonia risk by 5% and improve specialist evaluation resource efficiency by 20%. For 100,000 target patients, this translates to a potential market reduction of (~$13.5K × 100,000 × 0.05) + (~$2.0K × 100,000 × 0.20) = ~$50M + ~$40.0M = ~$90M (AI est.). From this, an annual economic impact of ~$10.0M (AI est.) could be generated.
X: Ease of Adoption & Cost Efficiency
Y: Detection Accuracy & Comfort